I remember in one of their calls a while back Retrophin refused to state how many patients in the Ph3 were staying on the upper dose (the study lets them step down) which doesnt sound massively encouraging for them in terms of the edema rates
I had a conversation with their CEO about a year ago and he couldn't give a straight answer about the decision to continue the higher of the two doses to Ph3, when they had just given a presentation highlighting the safety of the lower dose in Ph2.
I'm not sure sparsentan will be a magic bullet in fsgs by any stretch of the imagination
- Forums
- ASX - By Stock
- Oct 2
I remember in one of their calls a while back Retrophin refused...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
43.0¢ |
Change
-0.020(4.44%) |
Mkt cap ! $236.7M |
Open | High | Low | Value | Volume |
43.5¢ | 43.8¢ | 42.0¢ | $931.2K | 2.168M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 205332 | 42.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
43.0¢ | 114727 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 147449 | 0.425 |
20 | 411219 | 0.420 |
13 | 277111 | 0.415 |
12 | 233676 | 0.410 |
12 | 371408 | 0.405 |
Price($) | Vol. | No. |
---|---|---|
0.430 | 100612 | 7 |
0.435 | 63796 | 6 |
0.440 | 22500 | 3 |
0.445 | 55400 | 3 |
0.450 | 274993 | 7 |
Last trade - 15.40pm 04/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |